| 28 |
Tailoring Antiplatelet Therapy Is Still Necessary? |
Ki-Bae Seung |
May. 15. 12 |
| 27 |
What Is the Optimal Duration of DAPT Following DES Treatment? |
David E. Kandzari |
Jul. 22. 09 |
| 26 |
Anti-Platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib |
Roxana Mehran |
Jul. 22. 09 |
| 25 |
Does the Efficacy of Bivalirudin During PCI Depend on Clopidogrel Pretreatment? |
Matthew Price |
Jul. 22. 09 |
| 24 |
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Weight Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel, and Prasugrel) |
Gregg W. Stone |
Jul. 22. 09 |
| 23 |
New Paradigms in Treatment of ACS/AMI |
Roxana Mehran |
Jul. 22. 09 |
| 22 |
Not So Fast: The Data Are Circumstantial |
Ron Waksman |
Jul. 21. 09 |
| 21 |
Definitely: The Data Are Strong |
Matthew Price |
Jul. 21. 09 |
| 20 |
TRITON - TIMI 38: The Future Role of Prasugrel (and Other New Anti-Platelet Agents) in PCI |
Roxana Mehran |
Jun. 23. 09 |
| 19 |
The Role of Triple Antiplatelet Therapy in Patients with High Risk |
Young-Hoon Jeong |
May. 13. 09 |
